EVI1 Dysregulation: Impact on Biology and Therapy of Myeloid Malignancies

Overview

Journal Blood Cancer J

Date 2021 Mar 23

PMID 33753715

Citations 28

Authors

Christine Birdwell

Warren Fiskus

Tapan M Kadia

Courtney D DiNardo

Christopher P Mill

Kapil N Bhalla

Affiliations

Soon will be listed here.

Abstract

Ecotropic viral integration site 1 (Evi1) was discovered in 1988 as a common site of ecotropic viral integration resulting in myeloid malignancies in mice. EVI1 is an oncogenic zinc-finger transcription factor whose overexpression contributes to disease progression and an aggressive phenotype, correlating with poor clinical outcome in myeloid malignancies. Despite progress in understanding the biology of EVI1 dysregulation, significant improvements in therapeutic outcome remain elusive. Here, we highlight advances in understanding EVI1 biology and discuss how this new knowledge informs development of novel therapeutic interventions. EVI1 is overexpression is correlated with poor outcome in some epithelial cancers. However, the focus of this review is the genetic lesions, biology, and current therapeutics of myeloid malignancies overexpressing EVI1.

Citing Articles

Complex Genetic Evolution and Treatment Challenges in Myeloid Neoplasms: A Case of Persistent t(2;3)(p15~23;q26)/ Rearrangement, Mutation, and Transient Chimera.

Andersen K, Tjonnfjord G, Hestdalen M, Spetalen S, Panagopoulos I Cancer Genomics Proteomics. 2024; 22(1):24-33.

PMID: 39730178 PMC: 11696316. DOI: 10.21873/cgp.20483.

Evi1 governs Kdm6b-mediated histone demethylation to regulate the Laptm4b-driven mTOR pathway in hematopoietic progenitor cells.

Wu Q, Yu C, Yu F, Guo Y, Sheng Y, Li L J Clin Invest. 2024; 134(24).

PMID: 39680456 PMC: 11645144. DOI: 10.1172/JCI173403.

Clinical significance of dynamic monitoring of EVI1 gene expression in pediatric acute myeloid leukemia.

Zhang L, Li J, Wang Z, Yang L, Chen Z, Tao F BMC Pediatr. 2024; 24(1):802.

PMID: 39643863 PMC: 11622451. DOI: 10.1186/s12887-024-05243-7.

HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia.

Arza-Apalategi S, Heuts B, Bergevoet S, Meering R, Gilissen D, Jansen P Leukemia. 2024; 39(2):371-380.

PMID: 39633068 DOI: 10.1038/s41375-024-02485-3.

MECOM Locus classical transcript isoforms affect tumor immune microenvironment and different targets in ovarian cancer.

Lan N, Bai S, Chen M, Wang X, Feng Z, Gao Y J Ovarian Res. 2024; 17(1):207.

PMID: 39427186 PMC: 11490020. DOI: 10.1186/s13048-024-01522-0.

References

Summerer I, Haferlach C, Meggendorfer M, Kern W, Haferlach T, Stengel A . Prognosis of ()-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count. Leuk Lymphoma. 2020; 61(7):1756-1759. DOI: 10.1080/10428194.2020.1737689. View

Cui W, Sun J, Cotta C, Medeiros L, Lin P . Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia. Am J Clin Pathol. 2011; 136(2):282-8. DOI: 10.1309/AJCP48AJDCKTHUXC. View

Loven J, Hoke H, Lin C, Lau A, Orlando D, Vakoc C . Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013; 153(2):320-34. PMC: 3760967. DOI: 10.1016/j.cell.2013.03.036. View

Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S . The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature. 1998; 394(6688):92-6. DOI: 10.1038/27945. View

Pradhan A, Mohapatra A, Nayak K, Chakraborty S . Acetylation of the proto-oncogene EVI1 abrogates Bcl-xL promoter binding and induces apoptosis. PLoS One. 2011; 6(9):e25370. PMC: 3182211. DOI: 10.1371/journal.pone.0025370. View

Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, Imai Y . Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene. 2009; 28(49):4364-74. DOI: 10.1038/onc.2009.288. View

Ottema S, Mulet-Lazaro R, Beverloo H, Erpelinck C, van Herk S, van der Helm R . Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia. Blood. 2020; 136(2):224-234. DOI: 10.1182/blood.2019003701. View

Shimizu S, Nagasawa T, Katoh O, Komatsu N, Yokota J, Morishita K . EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation. Biochem Biophys Res Commun. 2002; 292(3):609-16. DOI: 10.1006/bbrc.2002.6693. View

Raynaud S, Baens M, Grosgeorge J, Rodgers K, Reid C, Dainton M . Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood. 1996; 88(2):682-9. View

10.

Bartholomew C, Kilbey A, Clark A, Walker M . The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene. 1997; 14(5):569-77. DOI: 10.1038/sj.onc.1200864. View

11.

Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern W . The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML. Leukemia. 2011; 25(5):874-7. DOI: 10.1038/leu.2011.5. View

12.

Saenz D, Fiskus W, Manshouri T, Mill C, Qian Y, Raina K . Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2018; 33(6):1373-1386. DOI: 10.1038/s41375-018-0334-3. View

13.

Manachai N, Saito Y, Nakahata S, Bahirvani A, Osato M, Morishita K . Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia. Biochem Biophys Res Commun. 2016; 482(4):994-1000. DOI: 10.1016/j.bbrc.2016.11.146. View

14.

Morishita K, Parganas E, Matsugi T, Ihle J . Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol. 1992; 12(1):183-9. PMC: 364082. DOI: 10.1128/mcb.12.1.183-189.1992. View

15.

Laricchia-Robbio L, Premanand K, Rinaldi C, Nucifora G . EVI1 Impairs myelopoiesis by deregulation of PU.1 function. Cancer Res. 2009; 69(4):1633-42. DOI: 10.1158/0008-5472.CAN-08-2562. View

16.

Lugthart S, Figueroa M, Bindels E, Skrabanek L, Valk P, Li Y . Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood. 2010; 117(1):234-41. PMC: 3037746. DOI: 10.1182/blood-2010-04-281337. View

17.

Akhter A, Farooq F, Elyamany G, Mughal M, Rashid-Kolvear F, Shabani-Rad M . Acute Myeloid Leukemia (AML): Upregulation of BAALC/MN1/MLLT11/EVI1 Gene Cluster Relate With Poor Overall Survival and a Possible Linkage With Coexpression of MYC/BCL2 Proteins. Appl Immunohistochem Mol Morphol. 2017; 26(7):483-488. DOI: 10.1097/PAI.0000000000000452. View

18.

Spensberger D, Delwel R . A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Lett. 2008; 582(18):2761-7. DOI: 10.1016/j.febslet.2008.06.056. View

19.

Takeshita M, Ichikawa M, Nitta E, Goyama S, Asai T, Ogawa S . AML1-Evi-1 specifically transforms hematopoietic stem cells through fusion of the entire Evi-1 sequence to AML1. Leukemia. 2008; 22(6):1241-9. DOI: 10.1038/leu.2008.53. View

20.

Shimahara A, Yamakawa N, Nishikata I, Morishita K . Acetylation of lysine 564 adjacent to the C-terminal binding protein-binding motif in EVI1 is crucial for transcriptional activation of GATA2. J Biol Chem. 2010; 285(22):16967-77. PMC: 2878005. DOI: 10.1074/jbc.M110.102046. View